Treatment of chronic hepatitis C with pegylated-interferon

Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication

Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFN^5. Case Presentation: In this report, we describe a case with se...

Treatment of chronic hepatitis delta with pegylated interferon-α2b

Background/Aims: Chronic hepatitis D is difficult to treat. The present pilot study investigated the efficacy and tolerability of pegylated (PEG)-interferon (IFN)-a2b in chronic hepatitis D. Patients and Methods: Twelve patients with chronic hepatitis D were prospectively treated with 1.5 mg/kg PEG-IFN-a2b for 48 weeks and followed for 24 weeks. Sustained response (SR) was defined as undetectab...

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C

Hepatitis flare is rarely observed during treatment with pegylated interferon alpha for hepatitis C virus (HCV) infection. A 49-year-old man receiving pegylated interferon α-2a for HCV infection had icterus and hyperbiliru-binemia in the 14th week of therapy, with HCV RNA undetectable after the 12th dose. Liver biopsy was suggestive of chronic hepatitis with cirrhosis without interface pattern....

optimizing treatment with pegylated interferon-ribavirin of genotype 3 chronic hepatitis c: more questions than answers

Safety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia

Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...